Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: An OPUS-TIMI 16 substudy

American Journal of Cardiology

Volumn 85, Issue 4, 2000, Pages 491-493

  Holmes, Michael B ^a   Sobel, Burton E ^a   Cannon, Christopher P ^b   Schneider, David J ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN; FIBRINOGEN RECEPTOR ANTAGONIST; ORBOFIBAN; PADGEM PROTEIN;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG BINDING; DRUG EFFICACY; FIBRINOGEN METABOLISM; FIBRINOLYTIC THERAPY; HUMAN; HUMAN CELL; HUMAN TISSUE; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE AGGREGATION INHIBITION;

ACUTE DISEASE; ADMINISTRATION, ORAL; ALANINE; BLOOD PLATELETS; CORONARY THROMBOSIS; FIBRINOGEN; HUMANS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PYRROLIDINES; RECURRENCE; THROMBOLYTIC THERAPY; TREATMENT OUTCOME;

EID: 0033954363     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00778-X     Document Type: Article

References (13)

1. Holmes M.B., Sobel B.E., Howard D.B., Schneider D.J. Differences between activation thresholds for platelet P-selectin and glycoprotein IIb-IIIa expression and their clinical implications. Thromb Res. 95:1999;75-82.
2. Ault K.A., Cannon C.P., Mitchell J., McCahan J., Tracy R.P., Novotny W.F., Reimann J.D., Braunwald E. Platelet activation in patients after an acute coronary syndrome results from the TIMI-12 trial . J Am Coll Cardiol. 33:1999;634-639.
3. Platelet glycoprotein IIb/IIIa receptor blockade and low dose heparin during percutaneous revascularization. N Engl J Med. 336:1997;1689-1696.
4. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 330:1994;956-961.
5. Platelet glycoprotein IIb/IIIa in unstable angina receptor suppression using integrilin therapy. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes . N Engl J Med. 339:1998;436-443.
6. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial ingarction. N Engl J Med. 338:1998;1488-1497.
7. Ferguson J.J. Meeting highlights highlights of the 48th Scientific Sessions of the American College of Cardiology . Circulation. 100:1999;570-575.
8. Rand M.D., Lock J.b., van't Veer C., Gaffney D.P., Mann K.G. Blood clotting in minimally altered whole blood. Blood. 88:1996;3432-3445.
9. Holmes M.B., Sobel B.E., Schneider D.J. Variable responses to inhibition of fibrinogen binding induced by tirofiban and eptifibatide in blood from healthy subjects. Am J Cardiol. 84:1999;203-207.
10. Schneider D.J., Taatjes D.J., Howard D., Sobel B.E. Increased reactivity of platelets induced by fibrinogen independent of its binding to the iib-iiia surface glycoprotein a potential contributor to cardiovascular risk . J Am Coll Cardiol. 33:1999;261-266.
11. Farrell T.P., Hayes K.B., Sobel B.E., Schneider D.J. The lack of augmentation by aspirin of inhibition of platelet reactivity by ticlopidine. Am J Cardiol. 83:1999;1-5.
12. Frelinger A., Du X., Plow E.F., Ginsburg M.H. Monoclonal antibodies to ligand-occupied conformers of glycoprotein IIb/IIIa alter receptor affinity, specificity and function. J Biol Chem. 266:1991;17106-17111.
13. Peter K., Schwarz M., Ylanne J., Kohler B., Moser M., Nordt T., Salbach P., Kubler W., Bode C. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb-IIIa inhibitors. Blood. 92:1998;3240-3249.